Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.03)
# 1,378
Out of 4,953 analysts
217
Total ratings
41.73%
Success rate
0.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics | Maintains: Overweight | $35 → $28 | $7.53 | +271.85% | 7 | Aug 18, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $20 → $21 | $8.75 | +140.00% | 4 | Aug 18, 2025 | |
| ERAS Erasca | Downgrades: Equal-Weight | $4 → $2 | $1.50 | +33.33% | 4 | Aug 18, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $17 → $13 | $7.09 | +83.36% | 6 | Aug 12, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $100 → $109 | $98.31 | +10.88% | 12 | Aug 6, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $165 → $162 | $118.68 | +36.50% | 8 | Aug 6, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $150 → $158 | $132.41 | +19.33% | 28 | Jul 31, 2025 | |
| FOLD Amicus Therapeutics | Upgrades: Overweight | $102 → $108 | $7.34 | +1,371.39% | 5 | Jul 17, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $65 → $55 | $29.25 | +88.03% | 9 | Jul 14, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $52 → $56 | $25.46 | +120.00% | 4 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $24.79 | -3.19% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $34 | $4.06 | +737.44% | 3 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $67 → $70 | $48.59 | +44.06% | 11 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $58.14 | +46.20% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $17.22 | +56.79% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $4.44 | +12.61% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $37.91 | +76.73% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $9.35 | +274.33% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $29.36 | +138.42% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $0.95 | +322.34% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $0.64 | +521.02% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $3.35 | +317.91% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $3.07 | +62.87% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $2.03 | +47.78% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.55 | +803.23% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $3.70 | +170.64% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $37.85 | -41.88% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $14.95 | +893.31% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.61 | +3,626.71% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.40 | +76.47% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $5.00 | +12,860.00% | 6 | May 8, 2020 |
Cullinan Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $7.53
Upside: +271.85%
Contineum Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $8.75
Upside: +140.00%
Erasca
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $1.50
Upside: +33.33%
Bicycle Therapeutics
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $7.09
Upside: +83.36%
Rhythm Pharmaceuticals
Aug 6, 2025
Maintains: Overweight
Price Target: $100 → $109
Current: $98.31
Upside: +10.88%
Jazz Pharmaceuticals
Aug 6, 2025
Maintains: Overweight
Price Target: $165 → $162
Current: $118.68
Upside: +36.50%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Overweight
Price Target: $150 → $158
Current: $132.41
Upside: +19.33%
Amicus Therapeutics
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $7.34
Upside: +1,371.39%
Ultragenyx Pharmaceutical
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $29.25
Upside: +88.03%
CG Oncology
Jun 17, 2025
Maintains: Overweight
Price Target: $52 → $56
Current: $25.46
Upside: +120.00%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $24.79
Upside: -3.19%
Mar 11, 2025
Maintains: Overweight
Price Target: $37 → $34
Current: $4.06
Upside: +737.44%
Mar 7, 2025
Assumes: Overweight
Price Target: $67 → $70
Current: $48.59
Upside: +44.06%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $58.14
Upside: +46.20%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $17.22
Upside: +56.79%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $4.44
Upside: +12.61%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $37.91
Upside: +76.73%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $9.35
Upside: +274.33%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $29.36
Upside: +138.42%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $0.95
Upside: +322.34%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $0.64
Upside: +521.02%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $3.35
Upside: +317.91%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $3.07
Upside: +62.87%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $2.03
Upside: +47.78%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.55
Upside: +803.23%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $3.70
Upside: +170.64%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $37.85
Upside: -41.88%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $14.95
Upside: +893.31%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.61
Upside: +3,626.71%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.40
Upside: +76.47%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $5.00
Upside: +12,860.00%